Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD… Read More
UBC researchers identify “molecular switch” that triggers precancerous changes in the esophagus—opening opportunities for early detection and prevention. A new UBC Faculty of Medicine study has revealed how long-term, chronic… Read More
VANCOUVER, BC – AbCellera (Nasdaq: ABCL) announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the… Read More
Genomics is no longer just about mapping DNA. Today, it’s powering new ways to fight infection, improve drug safety and deliver treatments straight to where they’re needed — even inside… Read More
British Columbians know the stark realities of climate change, as wildfires surge across the province. Over a million hectares burned across BC in 2024, blanketing communities in thick smoke and… Read More
